PEGylated IFNβ-1a in the treatment of multiple sclerosis

Expert Opinion on Biological Therapy

Volumn 15, Issue 7, 2015, Pages 1077-1084

  Khan, Umair Tahir ^a   Tanasescu, Radu ^a,b   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug evaluation; IFN; Multiple sclerosis; PEGIFN 1a; PEGylated; Relapse remitting multiple sclerosis; Review

Indexed keywords

NEOPTERIN; PEGINTERFERON BETA1A; BETA INTERFERON; MACROGOL DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DEPRESSION; DISABILITY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACODYNAMICS; RECURRENCE RISK; SUICIDAL IDEATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HALF LIFE TIME; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS; RECURRENCE; TREATMENT OUTCOME;

EID: 84931027204     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1053206     Document Type: Article

References (41)

1. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214-19
2. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nature Rev Neurol 2010;6(3):156-66
3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9(5):A387-94
4. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13(7):700-22
5. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30(3):233-67
6. Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013;12(11):1115-26
7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993 Apr;43(4):655-61
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39(3):285-94
9. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;Nov 7;352(9139):1498-504
10. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci 2011;302(1-2):96-105
11. Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann behave Med 2001;23(2):125-32
12. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009;6(9):995-1002
13. U.S. Food and Drug Administration. Novel New Drugs 2014 Summary. 2014. Available from: http://www.fda.gov [Last Accessed 15 April 2015]
14. European Medicines Agency. Plegridy: peginterferon beta-1a. 2015. Available from: http://www.ema. europa.eu/ema [Last Accessed 15 April 2015]
15. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89(2):225-40
16. Weinstock-Guttman B. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Am J Manag Care 2013;19(17 Suppl):s343-54
17. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012;18(5):610-15
18. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18(7):932-46
19. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Rel 2012;161(2):461-72
20. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs : clinical immunotherapeutics. Biopharm Gene Ther 2008;22(5):315-29
21. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6(1):1-16
22. Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008;25(5):403-47
23. Baker DP, Lin EY, Lin K, et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006;17(1):179-88
24. Baker DP, Pepinsky RB, Brickelmaier M, et al. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J interferon Cytokine Res 2010;30(10):777-85
25. Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 2005;22(1):58-61
26. Pepinsky RB, LePage DJ, Gill A, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001;297(3):1059-66
27. Reuss R, Pohle S, Retzlaff K, et al. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis. Neuroimmunomodulation 2009;16(3):171-6
28. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011;25(6):491-502
29. Hu X, Miller L, Richman S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 2012;52(6):798-808
30. Bagnato F, Durastanti V, Finamore L, et al. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003;24(Suppl 5):S301-4
31. Hu X, Cui Y, White J, et al. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. Br J Clin Pharmacol 2015;79(3):514-22
32. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-77
33. Liberati AM, Fizzotti M, Proietti MG, et al. Biochemical host response to interferon-beta. J Interferon Res 1988;8(6):765-77
34. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol 2015;55(2):179-88
35. Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Scler 2014 [Last Accessed 28 November 2014]
36. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13(7):657-65
37. European Medicines Agency. Plegridy: EU summary of product characteristics. 2014. Available from: http://www.ema. europa.eu
38. European Medicines Agency. Plegridy: assessment report. 2014. Available from: http://www.ema. europa.eu/ema/[Last Accessed 14 March 2015]
39. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference Adherence 2010;4:1-9
40. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38(4 Suppl 1):S2-6
41. Clotet B, Carmena J, Pulido F, et al. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials 2004;5(1):33-9